Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Subscribe To Our Newsletter & Stay Updated